Reitan Colleen F 4

What Happened Colleen F. Reitan, a director of Myriad Genetics, received a grant of 59,701 restricted stock units (RSUs) on June 4, 2026. The Form 4 reports an acquisition (award) at $0.00 per unit (i.e., a compensation grant, not an open‑market purchase or sale). The filing was submitted on June 5, 2026.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (within the normal 2‑business‑day window).
• Instrument: 59,701 restricted stock units (code A — award/grant).
• Reported price: $0.00 (compensatory grant); total cash paid: $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: RSUs granted under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. Each RSU represents a contingent right to one share and vests on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual meeting of stockholders.

Context This was a compensation grant (RSUs) to a director rather than a purchase or sale. RSUs convert to common shares only upon vesting, so they do not represent immediately tradable shares. Such awards are routine director compensation and should be interpreted as part of pay, not a direct market buy/sell signal.